Yoon Soo Hah

Dr. Yoon Soo Hah

Department of Urology, Catholic University of Daegu School of Medicine, Daegu 42472, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DKDo Kyung Kim
Do Kyung Kim
Joo Yong LeeJoo Yong Lee
Joo Yong Lee
KKKwang-il Kim
Kwang-il Kim
NHNamki Hong
Namki Hong
JKJong Won Kim
Jong Won Kim
KCKang Su Cho
Kang Su Cho
We aimed to evaluate the change in bone mineral density (BMD) in patients with prostate cancer (PCa) receiving androgen deprivation therapy (ADT) compared to those with PCa or other urologic conditions not receiving ADT. Literature searches were conducted throughout October 2018. The eligibility of each study was assessed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines using the Participant, Intervention, Comparator, Outcome, and Study design method. The outcomes analyzed were the mean difference (MD) of percent changes in BMD of lumbar spine, femur neck, and total hip. Five prospective cohort studies with a total of 533 patients were included in the present study. Statistically significant decreases of BMD change relative to the control group were observed in the ADT treatment group in the lumbar spine (MD −3.60, 95% CI −6.72 to −0.47, P = 0.02), femoral neck (MD −3.11, 95% CI −4.73 to −1.48, P = 0.0002), and total hip (MD −1.59, 95% CI −2.99 to −0.19, P = 0.03). There is a significant relationship between ADT and BMD reduction in patients with PCa. Regular BMD testing and the optimal treatment for BMD loss should, therefore, be considered in patients with PCa undergoing ADT.

1 March 2019 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
DKDo Kyung Kim
Do Kyung Kim
Joo Yong LeeJoo Yong Lee
Joo Yong Lee
JKJong Won Kim
Jong Won Kim
YHYoon Soo Hah
Yoon Soo Hah
KCKang Su Cho
Kang Su Cho

1 December 2012 in Urology
Verified
Journal Article
Closed access
WBWoo Jin Bang
Woo Jin Bang
HKHong Wook Kim
Hong Wook Kim
Joo Yong LeeJoo Yong Lee
Joo Yong Lee
DLDae Hoon Lee
Dae Hoon Lee
YHYoon Soo Hah
Yoon Soo Hah
KCKang Su Cho
Kang Su Cho

1 November 2012 in Journal of Urology
Verified
Journal Article
Closed access
YLYong Seung Lee
Yong Seung Lee
YHYoon Soo Hah
Yoon Soo Hah
MKMyung-Joon Kim
Myung-Joon Kim
HJHyun Jin Jung
Hyun Jin Jung
MLMi-Jung Lee
Mi-Jung Lee
SHSang Won Han
Sang Won Han
Ureteroureterostomy is a treatment modality for managing an ectopic ureterocele or ectopic ureter and preserving upper pole kidney function. However, the development of urinary tract infection at the residual ureteral stump is a concern. We analyzed factors affecting the development of urinary tract infection at the residual ureteral stump after proximal ureteroureterostomy. Between January 2002 and December 2009 proximal ureteroureterostomy was performed in 80 patients with ectopic ureterocele or ectopic ureter associated with a duplex system. Excluding 6 patients who did not meet the study inclusion criteria, we investigated age at operation, diameter of the upper pole ureter on ultrasonography, differential renal function and the presence of vesicoureteral reflux in 74 patients. Risk factors for residual ureteral stump infection and decreased differential renal function were analyzed. During a median followup of 5.0 years an additional operation was required in 9 patients (12.2%) due to urinary tract infection at the residual ureteral stump a median of 2.4 years after initial proximal ureteroureterostomy. The preoperative maximal diameter of the upper pole ureter was significantly greater in patients with infection complications. The postoperative maximal diameter of the upper pole ureter was also significantly greater on postoperative ultrasonography performed a median 43.0 days after the operation. Median preoperative and postoperative differential renal function was 47.8% and 47.0%, respectively. No preoperative factors were significantly related to the decrease in differential renal function. Proximal ureteroureterostomy is a safe treatment for ectopic ureterocele or ectopic ureter with a low postoperative complication rate. Upper pole ureter diameter was correlated with the development of a urinary tract infection at the residual ureteral stump.

31 March 2019 in International Neurourology Journal
Verified
Journal Article
Open access
PDF file
DKDo Kyung Kim
Do Kyung Kim
Joo Yong LeeJoo Yong Lee
Joo Yong Lee
JJJae Hung Jung
Jae Hung Jung
JKJae Heon Kim
Jae Heon Kim
YHYoon Soo Hah
Yoon Soo Hah
KCKang Su Cho
Kang Su Cho
To assess the effectiveness of alpha-1 adrenergic receptor blockers (α1-blockers) in the treatment of female lower urinary tract symptoms (LUTS). A literature search was conducted using the PubMed/MEDLINE, Embase, and Cochrane Library databases. Fourteen studies with 1,319 patients were ultimately included. The study comprised 2 analyses: a comparison of urinary symptom scores, maximal flow rate (Qmax), and postvoid residual (PVR) urine volume before and after α1-blocker administration in 8 prospective, open-label studies and 5 randomized clinical trials (RCTs); and an evaluation of the same variables in α1-blocker and placebo groups in 4 RCTs. The first meta-analysis showed that, following treatment, patients exhibited statistically significant symptom relief (mean difference [MD], -5.85; 95% confidence interval [CI], -7.71 to -3.99; P<0.00001), increased Qmax (MD, 3.67 mL/sec; 95% CI, 2.76-4.59 mL/sec; P<0.00001), and decreased PVR volume (MD, -28.46 mL; 95% CI, -34.99 to -21.93 mL; P<0.00001). In the second meta-analysis, α1-blockers demonstrated significant symptom relief relative to placebo (MD, -1.60; 95% CI, -2.68 to -0.51; P=0.004). However, no significant differences were observed in Qmax (MD, 0.05 mL/sec; 95% CI, -0.74 to 0.83 mL/sec, P=0.91) and PVR (MD, -8.10 mL; 95% CI, -32.32 to 16.12 mL, P=0.51) between the α1-blocker and placebo groups. These analyses suggest that α1-blockers are effective in the treatment of female LUTS patients. However, the effect of α1-blockers on female LUTS should be assessed according to the underlying cause, and the role of α1-blockers in combination therapy with other drugs should also be investigated.

15 August 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DKDong Hyuk Kang
Dong Hyuk Kang
Joo Yong LeeJoo Yong Lee
Joo Yong Lee
YHYoon Soo Hah
Yoon Soo Hah
DCDoo Yong Chung
Doo Yong Chung
DLDae Hun Lee
Dae Hun Lee
KCKang Su Cho
Kang Su Cho
To evaluate the effects of prostatic anatomical factors on male lower urinary tract symptoms (LUTS) and the peak flow rate (Qmax) in patients with small prostate volume (PV). Records were obtained from a prospectively maintained database of first-visit men with LUTS. Patients whose total PV (TPV) was greater than 30 mL were excluded; 444 patients were enrolled in the study. The TPV, transitional zone volume (TZV), transitional zone index (TZI), intravesical prostatic protrusion (IPP), and prostatic urethral angle (PUA) were measured by transrectal ultrasonography. LUTS were evaluated using the International Prostate Symptom Score (IPSS) and the Overactive Bladder Symptom Score (OABSS) questionnaires. Uroflowmetric measurements were also made. PUA (r = 0.269, P<0.001), TZV (r = 0.160, P<0.001), and TZI (r = 0.109, P = 0.022) significantly correlated with the IPSS. Qmax (r = −0.334, P<0.001) and OABSS (r = 0.211, P<0.001) correlated only with PUA. In a multivariate regression analysis, PUA and age were independently associated with IPSS, OABSS, and Qmax. For IPSS of 20 or greater, the area under the ROC curve (AUC) of PUA was 0.667 and the cut-off value was 43.7°. When Qmax was 10 mL/s or less, the AUC of PUA was 0.664 and the cut-off value was 43.5°. PUA has a significant association with symptom severity and Qmax among prostatic anatomical factors analyzed in men with LUTS and small PV. PUA should be considered as an important clinical factor in male LUTS management. Furthermore, the impact of PUA on response to medical treatment and disease progression needs to be investigated.